Crozier, Jennifer A <br/><br/>
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.  [electronic resource] 

 -  Cancer  Jul 2013 
 - 2447-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.28051  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--chemistry<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Body Mass Index<br/>Breast Neoplasms--chemistry<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Receptor, ErbB-2--analysis<br/>Receptors, Estrogen--analysis<br/>Receptors, Progesterone--analysis<br/>Trastuzumab<br/>Treatment Outcome